Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?
Fiche publication
Date publication
août 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric, Dr ANGELOT-DELETTRE Fanny
Tous les auteurs :
Poussard M, Angelot-Delettre F, Deconinck E
Lien Pubmed
Résumé
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. However, relapses frequently occur with the development of resistance. New options arising with the development of therapies targeting signaling pathways and epigenetic dysregulation have shown promising results. In this review, we focus on conventional therapies used to treat BPDCN and the novel therapeutic approaches that guide us toward the future management of BPDCN.
Mots clés
BPDCN, allogeneic stem cell transplantation, chemotherapies, conventional therapeutics, targeted therapies
Référence
Cancers (Basel). 2022 08 2;14(15):